Immunotherapy in urothelial cancer: current status and future directions-Reference-Cited by-同舟云学术

Immunotherapy in urothelial cancer: current status and future directions

Published:2023-10-04 Issue:11 Volume:23 Page:1141-1155
ISSN:1473-7140
Container-title:Expert Review of Anticancer Therapy
language:en
Short-container-title:Expert Review of Anticancer Therapy

Author:

Piombino Claudia¹,Tonni Elena¹,Oltrecolli Marco¹,Pirola Marta¹,Pipitone Stefania¹,Baldessari Cinzia¹,Dominici Massimo¹,Sabbatini Roberto¹,Vitale Maria Giuseppa¹

Affiliation:

1. Department of Oncology and Hematology, University Hospital of Modena, Modena, Italy

Funder

no funding

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Oncology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737140.2023.2265572

Reference132 articles.

1. GLOBAL CANCER OBSERVATORY [Internet]. Lyon (France): International Agency for Research on Cancer. 2023 [cited 2023 Apr 15]. Available from: https://gco.iarc.fr/

2. Epidemiology and Risk Factors of Urothelial Bladder Cancer

3. The Schedule and Duration of Intravesical Chemotherapy in Patients with Non–Muscle-Invasive Bladder Cancer: A Systematic Review of the Published Results of Randomized Clinical Trials

4. Bladder Cancer

5. Prognostic Performance and Reproducibility of the 1973 and 2004/2016 World Health Organization Grading Classification Systems in Non–muscle-invasive Bladder Cancer: A European Association of Urology Non-muscle Invasive Bladder Cancer Guidelines Panel Systematic Review

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Expression of transferrin receptor/TFRC protein in bladder cancer cell T24 and its role in inducing iron death in bladder cancer;International Journal of Biological Macromolecules;2024-08

2. The combination of immune checkpoint inhibitors and antibody-drug conjugates in the treatment of urogenital tumors: a review insights from phase 2 and 3 studies;Cell Death & Disease;2024-06-19

3. Urinary bother, Urinalysis, and Two-Year Efficacy Follow-Up Results of Phase I Trial of Intravesical Bacillus Calmette-Guérin Combined with Intravenous Pembrolizumab in Recurrent or Persistent High-Grade Non-Muscle-Invasive Bladder Cancer after Previous Bacillus Calmette-Guérin Treatment;Clinical Genitourinary Cancer;2024-06

4. Increased expression of ATP‐binding cassette transporters in enfortumab vedotin‐resistant urothelial cancer;IJU Case Reports;2024-01-29

5. The Effect of Sex on the Therapeutic Efficiency of Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis Based on Randomized Controlled Trials;Cancers;2024-01-16